Claudiximab - Ganymed Pharmaceuticals

Drug Profile

Claudiximab - Ganymed Pharmaceuticals

Alternative Names: IMAB 362

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ganymed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Claudin 18 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer
  • Preclinical Solid tumours
  • Discontinued Pancreatic cancer

Most Recent Events

  • 11 Dec 2017 Discontinued - Phase-I for Pancreatic cancer in Germany (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pancreatic-cancer in Germany (IV, Infusion)
  • 08 Sep 2017 Interim adverse events, efficacy and pharmacodynamics data from the phase I PILOT trial in Gastric cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top